Abionyx Pharma SA

ABIONYX Pharma SA is a biotechnology company that discovers and develops therapies for renal, metabolic, and ophthalmic diseases in France and the United States. It operates through two segments: Research and Development Activities for the Development of Innovative Drugs, and Contract Research Organization (CRO) Activities. The company is developing CER-001, a recombinant HDL mimetic biopharmaceutical, in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency and in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension of CER-001 into ophthalmology, in preclinical trials for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. It was incorporated in 2005 and is headquartered in Balma, France.